NASDAQ$NPCE
Neuropace Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
NeuroPace's Q1 2023 revenue increased, driven by RNS System utilization and DIXI Medical product distribution, while operating leverage improved through expense management.
NeuroPace reported a 27% year-over-year increase in revenue for Q1 2023, reaching $14.5 million. The growth was attributed to increased utilization of the RNS System and contributions from DIXI Medical products. The company increased its full-year revenue guidance to $52-$54 million.
- Total revenue reached $14.5 million, a 27% increase year-over-year.
- Gross margin was 72%, slightly down from 73% in Q1 2022 due to product mix changes.
- Operating expenses totaled $18.7 million, compared to $18.0 million in the prior year period.
- Full-year revenue guidance was increased to $52 million to $54 million.
Headline financials
Revenue & EPS history
Neuropace · Revenue · Quarterly
$14.5M
Revenue by segment
Neuropace · $1.6M total across 1 segment · Q4 2022
- DIXI Medical$1.6M—100.0%
Forward guidance
NeuroPace anticipates revenue growth will be primarily driven by increasing utilization of its RNS System and the full year impact of the sale of DIXI Medical stereo EEG products, partially offset by declining revenue from replacement device implants. The company expects gross margin to range between 69% and 71% and total operating expenses to range between $75 million and $77 million.
Tailwinds
- Revenue growth driven by increasing RNS System utilization
- Full year impact of DIXI Medical stereo EEG products
- Gross margin expected to range between 69% and 71%
- Focus on expanding addressable market
- Delivering clinical benefits of RNS System
Headwinds
- Declining revenue from replacement device implants
- Replacement implant revenue expected to decrease through 2023
- Uncertainty of COVID-19 pandemic impact
- Risks described in SEC filings
- Based on information available as of the report date
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-0.7%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.1%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+37.4%
Q3 2025
Best reaction
-40.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | -1.8% | — | |
| Q4 2025 | +1.1% | +1.6% | +5.9% | |
| Q3 2025 | +37.4% | +43.1% | +74.5% | |
| Q1 2025 | +21.6% | +31.3% | -14.5% | |
| Q4 2024 | -2.4% | -15.8% | +2.6% | |
| Q3 2024 | +25.7% | +23.4% | +49.9% | |
| Q2 2024 | -1.9% | -0.4% | +4.8% | |
| Q1 2024 | -40.1% | -35.9% | -51.4% | |
| Q4 2023 | +0.8% | +2.5% | -8.4% | |
| Q3 2023 | -1.4% | +9.5% | +14.6% | |
| Q2 2023 | +9.8% | +9.8% | +103.4% | |
| Q1 2023 | +1.9% | -3.5% | -15.4% | |
| Q4 2022 | -13.3% | -7.8% | -1.9% | |
| Q3 2022 | -9.9% | -17.6% | -29.6% | |
| Q2 2022 | -3.5% | -10.2% | -26.6% | |
| Q1 2022 | +1.2% | -3.6% | -3.8% | |
| Q4 2021 | -0.9% | -7.7% | -1.2% | |
| Q3 2020 | -15.2% | -22.2% | -47.7% | |
| Q3 2021 | -15.2% | -22.2% | -47.7% | |
| Q2 2021 | -7.6% | -10.7% | -8.0% | |
| Q2 2020 | -7.6% | -10.7% | -8.0% | |
| Q1 2020 | +0.8% | +8.7% | +2.2% | |
| Q1 2021 | +0.8% | +8.7% | +2.2% | |
| Q4 2020 | +0.8% | +8.7% | +2.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro